Predictors of outcome for advanced‐stage supraglottic laryngeal cancer

Ganly, Ian; Patel, Snehal G.; Matsuo, Jeanette; Singh, Bhuvanesh; Kraus, Dennis H.; Boyle, Jay; Wong, Richard J.; Lee, Nancy; Pfister, David G.; Shaha, Ashok R.; Shah, Jatin P.

doi:10.1002/hed.21113

Cited by 35 publications

(38 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multivariate analysis in supraglottic LSCC revealed that older age (>60 years), N2+ status and chemoradiotherapy were significant negative prognostic factors for OS, whereas T-status had no significant impact on outcomes. The negative impact of age and N+ status is consistent with the findings from Ganly et al [32], who investigated 182 cases of advanced-stage supraglottic LSCC treated at the Memorial Sloane-Kettering Cancer center. Contrary to the findings of Ganly et al , chemoradiotherapy showed a borderline negative associaton with OS in our cohort, whereas the remaining treatment modalities had no significant impact on the outcome.…”

Section: Discussionsupporting

confidence: 89%

Impact of stage, management and recurrence on survival rates in laryngeal cancer

et al. 2017

View full text Add to dashboard Cite

A retrospective, longitudinal study of 1,616 patients with primary laryngeal squamous cell carcinoma (LSCC) at a single center in Norway during 1983–2010 was undertaken to investigate overall survival, disease specific survival, disease-free survival, prognostic factors for overall survival, and impact of recurrence among all-stage laryngeal cancer patients over 15 years' follow-up. The prognostic impact of gender, age, smoking/alcohol, subsite, tumour, node and metastasis staging, period and modality of treatment were evaluated using Kaplan-Meier and Cox proportional hazard analyses. The importance of recurrence on survival was assessed based on case fatality rates. Five-year overall survival was 56.8%, 64.0% and 38.8%, and disease-specific survival was 80.2%, 87% and 61.6%, respectively, for the entire cohort and for glottic and supraglottic LSCC. Old age, advanced-stage LSCC and supraglottic cancer were associated with lower overall survival. The risk of disease-specific death plateaued after five years and varied significantly by subsite. Multivariate analysis of glottic LSCC revealed that surgical treatment improved overall survival, whereas old age, alcohol, T3-T4 status, positive N-status and no treatment were associated with worse survival. In supraglottic LSCC, age, alcohol, and positive N-status had a significant impact on overall survival by multivariate analysis. Five-year overall survival and disease-specific survival among patients with recurrent disease were 34% and 52%, respectively. In conclusion, marked difference in overall survival between glottic and supraglottic LSCC underline the importance of subsite-specific survival analysis. T-status and primary surgical management is essential only for glottic LSCC, emphasizing the importance of correct disease classification. Inferior outcomes in supraglottic LSCC are associated with old age, positive N-status, and improved follow-up routines are necessary. Primary tumor control is essential since recurrence impairs survival considerably in all subsites. The potential benefit of a primary surgical approach towards T3 LSCC awaits further investigation.

show abstract

Section: Discussionsupporting

confidence: 89%

Impact of stage, management and recurrence on survival rates in laryngeal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…24,25 LFI for patients with T3 or T4 laryngeal cancer after RT or CRT was 77% or higher after 5 years. This finding is in agreement with the literature.…”

Section: Discussionmentioning

confidence: 98%

Trends in treatment and survival for advanced laryngeal cancer: A 20‐year population‐based study in The Netherlands

Timmermans

Dijk

Overbeek³

et al. 2015

Head & Neck

View full text Add to dashboard Cite

show abstract

“…Thus it is clear that the major advantages of radiotherapy or chemoradiotherapy for treatment of advanced laryngeal cancer are avoidance of an operation and anatomic preservation of the larynx, with no definite compromise in overall survival 14,43,44. On the other hand, the disadvantages include a high incidence of severe acute toxicity, and a high incidence of long-term laryngeal functional problems, particularly in patients treated with concurrent chemoradiotherapy 35–38.…”

Section: Treatmentmentioning

confidence: 99%

Management of Advanced Laryngeal Cancer

Sheahan¹

2014

Rambam Maimonides Med J

View full text Add to dashboard Cite

Squamous cell carcinoma of the larynx continues to be the commonest head and neck cancer in many Western countries. The larynx plays a key role for many essential functions, including breathing, voice production, airway protection, and swallowing. The goals of laryngeal cancer treatment are thus to provide best possible oncologic control, while optimizing functional outcomes.In recent decades, the treatment paradigm for advanced laryngeal cancer has shifted from one of primary surgery (total laryngectomy) as gold standard, toward non-surgical organ-preserving treatment using radiotherapy or chemoradiotherapy. However, concerns have emerged regarding functional outcomes after chemoradiotherapy, as well as possible decreased overall survival in patients with laryngeal cancer.The purpose of the present review is to review surgical and non-surgical options for treatment of advanced laryngeal cancer, as well as the evidence supporting each of these.

show abstract

Predictors of outcome for advanced‐stage supraglottic laryngeal cancer

Abstract: Regardless of index treatment, age over 60 years and clinical stage of the neck at presentation were the main independent predictors of OS and DSS.

Cited by 35 publications

References 15 publications

Impact of stage, management and recurrence on survival rates in laryngeal cancer

Impact of stage, management and recurrence on survival rates in laryngeal cancer

Trends in treatment and survival for advanced laryngeal cancer: A 20‐year population‐based study in The Netherlands

Management of Advanced Laryngeal Cancer

Contact Info

Product

Resources

About